COVID-19 trials registries data warehouse

 Return to trial list

Trial - EUCTR2020-001928-34-SE


Column Value
Trial registration number EUCTR2020-001928-34-SE
Full text link
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

First author
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Capio S:t Görans Sjukhus - Gunilla Wahlström

Contact
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

gunilla.wahlstrom@capiostgoran.se

Registration date
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2020-04-24

Recruitment status
Last imported at : April 19, 2022, 4 a.m.
Source : EU Clinical Trials Register

Terminated

Study design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

RCT

Allocation
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Randomized

Design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Parallel

Masking
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Open label

Center
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

multi-center

Study aim
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Treatment

Inclusion criteria
Last imported at : Dec. 10, 2020, 1:30 a.m.
Source : EU Clinical Trials Register

1. Patients 18 years or older, who have signed informed consent for participation in the study 2. Hospitalized patients who have received oxygen therapy for maximum 48 hours 3. Verified Covid-19: Positive test for Sars-Cov-2-RNA or a positive Sars-Cov2 antigen test from upper respiratory tract 4. Receives oxygen therapy 5. Negative pregnancy test (female subjects of childbearing potential) 6. Female subjects of childbearing potential must use contraceptive method categorized as 'highly effective' according to CTFG during study treatment and 7 days after finished treatment. 1. Patienter 18 år eller äldre, som har givit sitt skriftliga samtycke till att delta i studien. 2. Vårdas inneliggande på sjukhus och har haft behandling med syrgas i maximalt 48 timmar 3. Verifierad Covid-19: Positivt prov för Sars-Cov2-RNA eller ett positivt Sars-Cov2 antigentest från övre luftvägar, det vill säga nasofarynx eller sputa. 4. Erhåller syrgasbehandling. 5. Negativt graviditetsprov (kvinnliga forskningspersoner i fertil ålder) 6. Villig att utöva antikonception kategoriserat som ”mycket effektiva” enligt Clinical Trial Facilitation Group under pågående studiebehandling + 7 dygn. (kvinnliga forskningspersoner i fertil ålder)

Exclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

1. Pregnancy, breast feeding or plans for pregnancy. 2. Known intolerance or hypersensitivity to ciclesonide or any of the other components of the study drug 3. Concomitant treatment with cortisone, ketoconazole, itraconazole, ritonavir or nelfinavir 4. Therapy with >8 L oxygen/min or therapy with >50 % oxygen through high flow nasal cannula 5. Ongoing palliative treatment or life expectancy less than 72 hours 6. Expected admission to ICU within 48 hours 7. Active or inactive tuberculosis 8. Severe liver disease (Child-Pugh C) 9. Pulmonary arterial hypertension (PAH) or fibrosis 10. Mental incapacity, unwillingness or language difficulties 11. Participation in another clinical trial within 30 days before inclusion in the present study. Earlier participation in the present study. 1. Graviditet, amning eller planerad graviditet. 2. Överkänslighet mot ciklesonid eller mot något hjälpämne. 3. Samtidig medicinering med kortison, ketokonazol, itrakonazol, ritonavir eller nelfinavir. 4. Behandling med >8 l syrgas /min eller tillförsel av >50 % syrgas med nasal högflödesgrimma 5. Pågående palliativt inriktad vård eller förväntad överlevnad mindre än 72 timmar. 6. Förväntad inskrivning på intensivvårdsavdelning inom 48 timmar. 7. Aktiv eller inaktiv lungtuberkulos. 8. Grav leversvikt (Child-Pugh C) 9. Diagnosticerad med pulmonell arteriell hypertension (PAH) eller fibros. 10. Mental oförmåga, ovilja eller språksvårigheter som medför svårighet att förstå innebörden av att delta i studien. 11. Deltar eller nyligen deltagit eller i en klinisk läkemedelsprövning den senaste 30 dagarna. Tidigare deltagande i denna studie.

Number of arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2

Funding
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Capio S:t Görans Sjukhus

Inclusion age min
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

18

Inclusion age max
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

100

Countries
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Sweden

Type of patients
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Moderate disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

3: Moderate disease at enrollment

Total sample size
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

446

primary outcome
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Number of days with oxygen therapy (30 days follow up after study inclusion). Terminated oxygen therapy is defined as discharge from hospital, without subsequent rehospitalization with oxygen therapy within 2 days, or at least 2 days without oxygen therapy for hospitalized patients. Antal dygn med syrgasbehandling (30 dagars uppföljning efter studieinklusion). Avslutad syrgasbehandling definieras som utskrivning till hemmet utan en återinskrivning med syrgasbehandling inom 2 dygn eller minst 2 dygn utan syrgasbehandling vid inneliggande vård. Det primära utfallsmåttet representerar ”klinisk förbättring” enligt en nominell skala som använts i tidigare studier på behandling av Covid-19 och som rekommenderas av WHO.

Notes
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

TODO

Phase
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Phase 2

Arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

[{"arm_notes": null, "treatment_id": 282, "treatment_name": "Ciclesonide", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": null, "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]